Related Experiment Videos
[Efficacy of oral bepridil in ventricular arrhythmias in stable coronary insufficiency]
Insights
Bepridil shows antiarrhythmic effects in patients with coronary insufficiency and ventricular arrhythmias. Higher doses (500 mg/day) demonstrated greater efficacy than lower doses (300 mg/day).
Area of Science:
- Cardiology
- Pharmacology
Background:
- Bepridil's electrophysiological properties suggest potential for treating ventricular arrhythmias.
- Stable coronary insufficiency patients with significant ventricular arrhythmias require effective treatment.
Purpose of the Study:
- To evaluate the antiarrhythmic efficacy of oral bepridil in patients with stable coronary insufficiency and ventricular arrhythmias.
- To determine the optimal dosage for bepridil's antiarrhythmic effect.
Main Methods:
- Prospective, multicentre trial involving patients with >1000 ventricular extrasystoles/24h or ventricular tachycardia.
- Patients were divided into three groups based on arrhythmia type and bepridil dosage (300 mg/day or 500 mg/day).
- Efficacy assessed by reduction in ventricular extrasystoles and suppression of complex ventricular extrasystoles.
Main Results:
- At 300 mg/day, 27% of patients (12/44) showed favorable responses.
- Increasing dosage to 500 mg/day in non-responders yielded a 68.4% efficacy rate (13/19).
- Bepridil was effective in 3/6 cases of ventricular tachycardia, with one case combined with amiodarone.
Conclusions:
- Oral bepridil exhibits an antiarrhythmic effect in patients with stable coronary insufficiency and ventricular arrhythmias.
- The antiarrhythmic effect is modest at 300 mg/day but more pronounced at 500 mg/day.
- Bepridil represents a potential therapeutic option for managing these specific cardiac arrhythmias.
Abstract:
The electrophysiological properties of bepridil suggest a possible ventricular antiarrhythmic effect. This prospective multicentre trial was undertaken to study the antiarrhythmic efficacy of oral bepridil on ventricular arrhythmias in patients with stable coronary insufficiency and more than 1 000 ventricular extrasystoles per 24 hours or ventricular tachycardia. The patients were divided into 3 groups according to the arrhythmias observed and the dosage used. In group I, the dosage was 300 mg/day and 12 out of 44 patients (27%) responded favourably to two criteria of efficacy (decrease of 84% of the number of ventricular extrasystoles; suppression of complex ventricular extrasystoles). In group II, the dosage was 300 mg/day, and then increased to 500 mg in non responders. Using the same criteria of efficacy, 13 out of 19 positive results were observed (68.4%). Group III comprised all cases of ventricular tachycardia; bepridil was effective in 3 out of 6 cases, associated with amiodarone in 1 case. The results demonstrate an antiarrhythmic effect of bepridil which is modest at 300 mg/day but which becomes more marked at the dosage of 500 mg/day.